Emerging Safety Science : Workshop Summary PDF
by Institute of Medicine, Board on Health Sciences Policy, Development, and Translation Forum on Drug Discovery, Robert Giffin, Robert Pool, Sally Robinson
- Information
Description
In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (DiMasi and Grabowski, 2007). At the same time, each year fewer new molecular entities (NMEs) are approved. DiMasi and Grabowski report that only 21.5 percent of the candidate drugs that enter phase I clinical testing actually make it to market. In 2007, just 17 novel drugs and 2 novel biologics were approved. In addition to the slowing rate of drug development and approval, recent years have seen a number of drugs withdrawn from the market for safety reasons. According to the Government Accountability Office (GAO), 10 drugs were withdrawn because of safety concerns between 2000 and March 2006 (GAO, 2006). Finding ways to select successful drug candidates earlier in development could save millions or even billions of dollars, reduce the costs of drugs on the market, and increase the number of new drugs with improved safety profiles that are available to patients.
Information
-
Download Now
- Format:PDF
- Pages:150 pages
- Publisher:National Academies Press
- Publication Date:08/04/2008
- Category:
- ISBN:9780309110136
Other Formats
- EPUB from £43.19
Information
-
Download Now
- Format:PDF
- Pages:150 pages
- Publisher:National Academies Press
- Publication Date:08/04/2008
- Category:
- ISBN:9780309110136